Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Recurrent Atrial Fibrillation
This trial is active, not recruiting.
|Sponsor||VZW Cardiovascular Research Center Aalst|
|Collaborator||AZ Sint-Jan AV|
|Start date||March 2014|
|End date||August 2016|
|Trial size||152 participants|
|Trial identifier||NCT02475642, POWDER-AF01|
The purpose of this study is to compare the efficacy and safety of PV isolation with continued antiarrhythmic drug treatment (PVI+ADT) to PV isolation without continued ADT (PVI-ADT) in patients undergoing treatment for symptomatic recurrent AF.
|Endpoint classification||safety/efficacy study|
|Intervention model||parallel assignment|
Efficacy as measured by freedom of arrhythmia recurrence
time frame: 9 months
Safety as measured by drug discontinuation
time frame: 9 months
Male or female participants at least 18 years old.
Inclusion Criteria: - patient has continued (IC or III) ADT throughout the 3-month blanking - patient is free of symptomatic and asymptomatic AF (as evidenced by 1-day Holter) at the 3-month visit - drug-resistant (at least one class IC or III) symptomatic AF was the primary indication for prior PV isolation - in the three months prior to PVI, at least one episode of symptomatic or asymptomatic AF - PV isolation was performed according to the standards set forward by the Task Force Document (sedation or general anesthesia) - PV isolation was the only target for ablation (except for cavotricuspid (CTI) ablation if documented AFL) - PV isolation was performed by point-by-point irrigated radio frequency (RF) guided by contact-force (Biosense) (10-30gr-continuous lesion) - PV isolation (i.e. entry block) was verified in each vein after a waiting time and adenosine (with continued RF if acute reconnection) - Signed Patient Informed Consent Form. - Age 18 years or older. - Able and willing to comply with all follow-up testing and requirements. Exclusion Criteria: - Longstanding persistent atrial fibrillation (>12 months of continuous AF) - Previous ablation for AF - left atrium (LA) size > 55 mm - left ventricular ejection fraction (LVEF) < 40% - AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause - coronary artery bypass graft (CABG) procedure within the last six months - Awaiting cardiac transplantation or other cardiac surgery - Documented left atrial thrombus on imaging - Diagnosed atrial myxoma - Women who are pregnant (by history of menstrual period or pregnancy test if the history is considered unreliable) or breastfeeding - Acute illness or active systemic infection or sepsis - Unstable angina - Uncontrolled heart failure - Myocardial infarction within the previous two (2) months - History of blood clotting or bleeding abnormalities - Contraindication to anticoagulation therapy (ie, heparin or warfarin) - Life expectancy less than 12 months - Enrollment in any other study evaluating another device or drug - Presence of intramural thrombus, tumor or other abnormality that precludes catheter introduction - Patients not taking any class IC or III ADT at 3 months after PV isolation - No documentation of entry block at initial PV isolation - no waiting time or adenosine. - Additional linear ablation or defractionation during the initial procedure (except for CTI ablation for documented or induced cavo-tricuspid isthmus dependent flutter).
|Official title||Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Recurrent Atrial Fibrillation: A Prospective 2-Centre Randomized Controlled Clinical Study (POWDER-AF)|
|Principal investigator||Mattias Duytschaever, MD, PhD|
|Description||Subjects that underwent PV isolation for paroxysmal or non-longstanding persistent AF and are free of arrhythmia at the end of the 3-month blanking period while taking ADT. Eligible subjects who sign the study informed consent form will be randomized into one of two study arms: PVI+ADT Group: continue ADT through 9 months follow-up PVI-ADT Group: no ADT through 9 months follow up|
Call for more information